October 2, 2017 07:56 AM EDT
People
R&D
Pharma

Sam Kulka­rni takes the helm at CRISPR Ther­a­peu­tics as found­ing CEO steps down

John Carroll

Editor & Founder

Af­ter steer­ing CRISPR Ther­a­peu­tics to an IPO last year as the last of the big three gene edit­ing com­pa­nies to make the leap in­to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

TRENDING NOW

Up­dat­ed: Zealand part­ners with Roche on its amylin ana­log in a deal worth up to $5.3B

FDA’s med­ical re­view de­part­ments re­main un­touched (for now) by Musk’s cuts

Arv­inas, Pfiz­er’s PRO­TAC da­ta fall short of hype in breast can­cer

Gilead plans to skip from Phase 1 to Phase 3 with once-year­ly HIV pre­ven­tion drug

Cor­rect­ed: Mer­ck opens bil­lion-dol­lar US fa­cil­i­ty to make Gar­dasil

sponsored

Obe­si­ty drug de­vel­op­ment—still room to grow

A service from the Financial Times